Gelonghui, Feb. 27 丨 China Resources Healthcare (1515.HK) rose more than 4% to HK$657, with a total market capitalization of HK$8.52 billion. According to GF Securities's latest report, maintaining China Resources Healthcare's “buy” rating, if Liao Jianjiang's parallel performance is not taken into account, the net profit returned to the mother in 23 is predicted to be 533 million yuan. Hospital operations resumed in '23, targets were merged, and profitability is still improving. The bank believes the company's reasonable target price is HK$9.46. In addition, the company recently plans to acquire the medical business for more than 3.6 billion yuan, and the scale of the business will expand further.